These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24206883)

  • 21. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial.
    Ellert J; Maeng M; Raungaard B; Hansen KN; Kahlert J; Jensen SE; Bøtker HE; Hansen HS; Lassen JF; Christiansen EH; Jensen LO
    Coron Artery Dis; 2020 Sep; 31(6):485-492. PubMed ID: 32271243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents.
    Jakobsen L; Christiansen EH; Maeng M; Hansen KN; Kristensen SD; Bøtker HE; Terkelsen CJ; Jensen SE; Raungaard B; Madsen M; Lassen JF; Jensen LO
    EuroIntervention; 2017 Dec; 13(11):1336-1344. PubMed ID: 28846543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).
    Park KH; Jeong MH; Hong YJ; Ahn Y; Kim HK; Koh YY; Kim DI; Kim SW; Kim W; Rha SW; Rhew JY; Park JS; Park HS; Bae JH; Bae JW; Oh SK; Lee SY; Lee SW; Lee JH; Lim SY; Cho JH; Cha KS; Chae JK; Hur SH; Hwang SH; Hwang JY
    Yonsei Med J; 2018 Jan; 59(1):72-79. PubMed ID: 29214779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
    Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
    Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
    Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.
    Nakamura M; Otsuka Y; Ueda Y; Mitsudo K
    Cardiovasc Interv Ther; 2012 Jan; 27(1):24-30. PubMed ID: 24122637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study.
    Andreasen LN; Holm NR; Balleby IR; Krusell LR; Maeng M; Jakobsen L; Veien KT; Hansen KN; Kristensen SD; Hjort J; Kaltoft A; Dijkstra J; Terkelsen CJ; Lassen JF; Madsen M; Bøtker HE; Jensen LO; Christiansen EH
    Eur Heart J Cardiovasc Imaging; 2018 Mar; 19(3):329-338. PubMed ID: 28369332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
    de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Jüni P; Kastrati A; Windecker S
    Int J Cardiol; 2013 Oct; 168(6):5162-6. PubMed ID: 23993323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).
    Maeng M; Christiansen EH; Raungaard B; Kahlert J; Terkelsen CJ; Kristensen SD; Carstensen S; Aarøe J; Jensen SE; Villadsen AB; Lassen JF; Thim T; Eftekhari A; Veien KT; Hansen KN; Junker A; Bøtker HE; Jensen LO;
    JACC Cardiovasc Interv; 2019 Apr; 12(7):624-633. PubMed ID: 30947936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravascular imaging comparison of two metallic limus-eluting stents abluminally coated with biodegradable polymers: IVUS and OCT results of the DESTINY trial.
    Costa JR; Chamié D; Abizaid AA; Ribeiro E; Meireles GC; Prudente M; Campos CA; Castro JP; Costa R; Lemos PA
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):161-168. PubMed ID: 27714601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy outcomes of 3rd generation DES in an all-comer population of patients undergoing PCI: 12-month and 24-month results of the e-Biomatrix French registry.
    Maupas E; Lipiecki J; Levy R; Faurie B; Karsenty B; Moulichon ME; Brunelle F; Maillard L; de Poli F; Lefèvre T
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):890-897. PubMed ID: 28544186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.